ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
High GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impact Results to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 SAN CARLOS, Calif., January 06, 2026 BUSINESS WIRE BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA ® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA ® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 me
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals price target raised to $235 from $210 at Needham [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Truist Financial Corporation from $220.00 to $230.00. They now have a "buy" rating on the stock.MarketBeat
- Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Needham & Company LLC from $210.00 to $235.00. They now have a "buy" rating on the stock.MarketBeat
- Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain [Yahoo! Finance]Yahoo! Finance
- Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 11/5/25 - Beat
JAZZ
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form 4
- 12/11/25 - Form 4
- JAZZ's page on the SEC website